Peter van, MD
Nephrology · Covington, LANPI 1134330400
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,843, 3.9 times the $478 reported in 2019.
Across 276 payments — averaging $29.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$1K
- AstraZeneca$1K
- Amgen$640
- Travere Therapeutics, Inc.$547
- Melinta Therapeutics, LLC$494
- Otsuka America Pharmaceutical, Inc.$448
- plus $4K from 25 others
What the payments were for
- Food & beverage$7,85398%
- Education$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 57 | $1,187 |
| AstraZeneca | 30 | $1,003 |
| Amgen(2 entities) | 21 | $640 |
| Travere Therapeutics, Inc. | 12 | $547 |
| Melinta Therapeutics, LLC | 4 | $494 |
| Otsuka America Pharmaceutical, Inc. | 21 | $448 |
| AbbVie(2 entities) | 4 | $426 |
| Mallinckrodt Hospital Products Inc. | 19 | $394 |
| Paratek Pharmaceuticals, Inc. | 3 | $375 |
| Calliditas Therapeutics US Inc. | 12 | $355 |
| Bayer | 19 | $343 |
| Shionogi Inc | 2 | $244 |
| Akebia Therapeutics Inc | 9 | $180 |
| Novartis | 7 | $132 |
| Vifor Pharma, Inc. | 7 | $130 |
| OPKO Pharmaceuticals, LLC | 8 | $126 |
| Viiv Healthcare Company | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 5 | $113 |
| Boehringer Ingelheim | 6 | $109 |
| Sanofi | 4 | $100 |
| Daiichi Sankyo Inc. | 5 | $92 |
| GSK | 5 | $91 |
| La Jolla Pharmaceutical Company | 1 | $89 |
| ANI Pharmaceuticals, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Novo Nordisk | 2 | $44 |
| Veloxis Pharmaceuticals, Inc. | 2 | $39 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $19 |
| Nxstage Medical, Inc. | 1 | $18 |
| Pfizer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,017 in reported general payments places this provider in the 80th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 34 | $113,629 |
| Sevelamer Carbonate | 111 | $28,902 |
| FarxigaDapagliflozin Propanediol | 29 | $21,784 |
| KerendiaFinerenone | 18 | $13,810 |
| InvokanaCanagliflozin | 19 | $11,107 |
| LinzessLinaclotide | 13 | $6,862 |
| Cinacalcet Hcl | 47 | $5,105 |
| Calcium Acetate | 13 | $1,796 |
| Calcitriol | 117 | $1,775 |
| Losartan Potassium | 96 | $1,273 |
| Clonidine | 11 | $1,184 |
| Bumetanide | 32 | $765 |
| Hydralazine Hcl | 64 | $724 |
| Spironolactone | 74 | $541 |
| Potassium Chloride | 22 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $1,187 | $113,62934 claims |
| AstraZenecaFarxiga | $1,003 | $21,78429 claims |
| BayerKerendia | $343 | $13,81018 claims |
| AbbVieLinzess | $426 | $6,86213 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $62 | $9111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Covington
- Jon MaresCovington$103K
- David PowersCovington$35K
- Imran ShujaCovington$5K
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.